Insulet Stock Forecast, Price & News

Insulet's stock was trading at $172.11 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PODD stock has increased by 30.5% and is now trading at $224.57.
View which stocks have been most impacted by COVID-19.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 1 sell rating, 11 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Insulet.

Insulet is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Insulet.

Insulet Co. (NASDAQ:PODD) released its quarterly earnings results on Thursday, August, 6th. The medical instruments supplier reported $0.22 EPS for the quarter, beating analysts' consensus estimates of ($0.01) by $0.23. The medical instruments supplier earned $226.30 million during the quarter, compared to the consensus estimate of $212.41 million. Insulet had a return on equity of 10.96% and a net margin of 2.20%. The company's revenue was up 27.8% compared to the same quarter last year. During the same period last year, the firm earned $0.02 EPS.
View Insulet's earnings history.

Insulet issued an update on its FY 2020 After-Hours earnings guidance on Thursday, August, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $863.694-878.458 million, compared to the consensus revenue estimate of $849.76 million.

20 brokers have issued 12-month price targets for Insulet's stock. Their forecasts range from $165.00 to $260.00. On average, they anticipate Insulet's share price to reach $223.00 in the next twelve months. This suggests that the stock has a possible downside of 0.7%.
View analysts' price targets for Insulet.

Insulet saw a increase in short interest during the month of August. As of August 14th, there was short interest totaling 2,840,000 shares, an increase of 10.1% from the July 30th total of 2,580,000 shares. Based on an average trading volume of 494,300 shares, the short-interest ratio is presently 5.7 days.
View Insulet's Short Interest.

Some companies that are related to Insulet include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Hologic (HOLX), Varian Medical Systems (VAR), Teleflex (TFX) and Steris (STE).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Walt Disney (DIS), Square (SQ), salesforce.com (CRM), Tesla (TSLA), Trade Desk (TTD) and Roku (ROKU).

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Insulet's stock is owned by a number of institutional and retail investors. Top institutional investors include Mint Tower Capital Management B.V. (12.74%), Vanguard Group Inc. (9.07%), Coatue Management LLC (2.22%), William Blair Investment Management LLC (1.43%), Frontier Capital Management Co. LLC (1.29%) and Marshall Wace North America L.P. (1.12%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Bret Christensen, Charles Alpuche, Corinne H Nevinny, David A Lemoine, David Colleran, Eric Benjamin, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic.
View institutional ownership trends for Insulet.

PODD stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Perceptive Advisors LLC, Victory Capital Management Inc., Marshall Wace North America L.P., Russell Investments Group Ltd., Federated Hermes Inc., Chartwell Investment Partners LLC, and First Trust Advisors LP. Company insiders that have sold Insulet company stock in the last year include Bret Christensen, Charles Alpuche, Corinne H Nevinny, David A Lemoine, Eric Benjamin, John A Fallon, Michael P Spears, and Shacey Petrovic.
View insider buying and selling activity for Insulet.

PODD stock was acquired by a variety of institutional investors in the last quarter, including Mint Tower Capital Management B.V., Holocene Advisors LP, Vanguard Group Inc., Goldman Sachs Group Inc., Alyeska Investment Group L.P., Bellevue Group AG, SeaTown Holdings Pte. Ltd., and Tobam.
View insider buying and selling activity for Insulet.

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PODD stock can currently be purchased for approximately $224.57.

Insulet has a market capitalization of $14.74 billion and generates $738.20 million in revenue each year. The medical instruments supplier earns $11.60 million in net income (profit) each year or $0.19 on an earnings per share basis. Insulet employs 1,350 workers across the globe.

The official website for Insulet is www.insulet.com.

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]